Related Experiment Video

Updated: May 8, 2026

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Integrating Somatic and Germline Pharmacogenomics for Therapeutic Decisions in Precision Oncology

Vai S Pathak1,2, Courtney E Hershberger1,2, Suneel Kamath3

  • 1Department of Quantitative Health Sciences, Cleveland Clinic Research, Cleveland Clinic, Cleveland, OH.

JCO Precision Oncology
|May 6, 2026
PubMed
Abstract

Insights

Actionable germline pharmacogenomic (PGx) variants are nearly universal in cancer patients, impacting drug dosing and toxicity. Integrating PGx with somatic profiling enhances precision medicine and minimizes adverse effects.

Area of Science:

  • Oncology
  • Genomics
  • Pharmacogenomics

Background:

  • Clinical genomic profiling identifies tumor targets.
  • Germline pharmacogenomics (PGx) guides drug dosing and toxicity management.
  • The combined landscape of somatic and germline actionable variants in cancer is not well-defined.

Purpose of the Study:

  • To comprehensively define the clinical landscape of actionable somatic and germline variants in cancer patients.
  • To construct an integrated germline-somatic PGx profile for each patient.

Main Methods:

  • Whole-exome sequencing data from 10,302 The Cancer Genome Atlas patients (tumor and germline).
  • Somatic mutations mapped to FDA-approved drugs using Oncology Knowledge Base.
  • Germline PGx variants identified using PyPGx and cross-referenced with PharmGKB.

Main Results:

  • All patients (100%) had actionable germline PGx variants (median 3).
  • 73% had variants relevant to chemotherapy toxicity or supportive care (e.g., DPYD, UGT1A1).
  • 42% had actionable somatic mutations for targeted therapy (e.g., PIK3CA, KRAS).

Conclusions:

  • Actionable germline variants are nearly universal, impacting toxicity and supportive care.
  • Combined germline and somatic sequencing can enhance therapeutic precision.
  • Routine implementation can minimize adverse effects and inform individualized treatment.

More Related Videos

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies13:24

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies

Published on: April 11, 2016

Genetic Profiling and Genome-Scale Dropout Screening to Identify Therapeutic Targets in Mouse Models of Malignant Peripheral Nerve Sheath Tumor09:33

Genetic Profiling and Genome-Scale Dropout Screening to Identify Therapeutic Targets in Mouse Models of Malignant Peripheral Nerve Sheath Tumor

Published on: August 25, 2023

Related Concept Videos

Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Pharmacogenetics and Pharmacogenomics: Overview01:29

Pharmacogenetics and Pharmacogenomics: Overview

Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...